tirzepatide fda label mounjaro prescribing information pdf Mounjaro Injection: Package Insert / Prescribing Info / MOA FDA Approves Mounjaro (tirzepatide) Injection

Large clinical trials and post-marketing surveillance have not identified increased venous thromboembolism risk, and regulatory bodies have not issued warnings regarding thrombotic events as a class effect

Fix: Source from reputable suppliers with third-party testing

Always account for the longest-lasting compound in your protocol when planning a washout phase

These modifications protect against degradation by dipeptidyl peptidase-4 (DPP-4), an enzyme that would otherwise chew through the molecule in minutes

J.TrehanI.Dominguez-BelloM

Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis